Literature DB >> 11032332

Acylcarnitines in plasma and blood spots of patients with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase defiency.

J L Van Hove1, S G Kahler, M D Feezor, J P Ramakrishna, P Hart, W R Treem, J J Shen, D Matern, D S Millington.   

Abstract

The acylcarnitines in plasma and blood spots of 23 patients with proven deficiency of long-chain 3-hydroxyacylcoenzyme A dehydrogenase were reviewed. Long-chain 3-hydroxyacylcarnitines of C14:1, C14, C16 and C18:1 chain length, and long-chain acylcarnitines of C12, C14:1, C14, C16, C18:2 and C18:1 chain length were elevated. Acetylcarnitine was decreased. In plasma, elevation of hydroxy-C18:1 acylcarnitine over the 95th centile of controls, in combination with an elevation of two of the three acylcarnitines C14, C14:1 and hydroxy-C16, identified over 85% of patients with high specificity (less than 0.1% false positive rate). High endogenous levels of long-chain acylcarnitines in normal erythrocytes reduced the diagnostic specificity in blood spots compared with plasma samples. The results were also diagnostic in asymptomatic patients, and were not influenced by genotype. Treatment with diet low in fat and high in medium-chain triglyceride decreased all disease-specific acylcarnitines, often to normal, suggesting that this assay is useful in treatment monitoring.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032332     DOI: 10.1023/a:1005673828469

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  23 in total

1.  Progressive neuropathy and recurrent myoglobinuria in a child with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency.

Authors:  C Dionisi Vici; A B Burlina; E Bertini; C Bachmann; M R Mazziotta; F Zacchello; G Sabetta; D E Hale
Journal:  J Pediatr       Date:  1991-05       Impact factor: 4.406

2.  Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders.

Authors:  J J Shen; D Matern; D S Millington; S Hillman; M D Feezor; M J Bennett; M Qumsiyeh; S G Kahler; Y T Chen; J L Van Hove
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

3.  Common missense mutation G1528C in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Characterization and expression of the mutant protein, mutation analysis on genomic DNA and chromosomal localization of the mitochondrial trifunctional protein alpha subunit gene.

Authors:  L IJlst; J P Ruiter; J M Hoovers; M E Jakobs; R J Wanders
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

4.  A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women.

Authors:  J A Ibdah; M J Bennett; P Rinaldo; Y Zhao; B Gibson; H F Sims; A W Strauss
Journal:  N Engl J Med       Date:  1999-06-03       Impact factor: 91.245

5.  Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry.

Authors:  D H Chace; D S Millington; N Terada; S G Kahler; C R Roe; L F Hofman
Journal:  Clin Chem       Date:  1993-01       Impact factor: 8.327

Review 6.  Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications.

Authors:  A W Strauss; M J Bennett; P Rinaldo; H F Sims; L K O'Brien; Y Zhao; B Gibson; J Ibdah
Journal:  Semin Perinatol       Date:  1999-04       Impact factor: 3.300

7.  3-Hydroxydicarboxylic aciduria due to long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency associated with sudden neonatal death: protective effect of medium-chain triglyceride treatment.

Authors:  M Duran; R J Wanders; J P de Jager; L Dorland; L Bruinvis; D Ketting; L Ijlst; F J van Sprang
Journal:  Eur J Pediatr       Date:  1991-01       Impact factor: 3.183

8.  Detection of inborn errors of fatty acid oxidation from acylcarnitine analysis of plasma and blood spots with the radioisotopic exchange-high-performance liquid chromatographic method.

Authors:  E Schmidt-Sommerfeld; D Penn; M Duran; M J Bennett; R Santer; C A Stanley
Journal:  J Pediatr       Date:  1993-05       Impact factor: 4.406

9.  The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy.

Authors:  H F Sims; J C Brackett; C K Powell; W R Treem; D E Hale; M J Bennett; B Gibson; S Shapiro; A W Strauss
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

Review 10.  The clinical spectrum of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.

Authors:  R Pons; M Roig; E Riudor; A Ribes; P Briones; L Ortigosa; A Baldellou; J Gil-Gibernau; M Olesti; C Navarro; R J Wanders
Journal:  Pediatr Neurol       Date:  1996-04       Impact factor: 3.372

View more
  14 in total

1.  Effect of optimal dietary therapy upon visual function in children with long-chain 3-hydroxyacyl CoA dehydrogenase and trifunctional protein deficiency.

Authors:  Melanie B Gillingham; Richard G Weleber; Martha Neuringer; William E Connor; Monte Mills; Sandy van Calcar; James Ver Hoeve; Jon Wolff; Cary O Harding
Journal:  Mol Genet Metab       Date:  2005-07-22       Impact factor: 4.797

2.  Performance of serum and dried blood spot acylcarnitine profiles for detection of fatty acid β-oxidation disorders in adult patients with rhabdomyolysis.

Authors:  Khalid Al-Thihli; Graham Sinclair; Sandra Sirrs; Michelle Mezei; Judie Nelson; Hilary Vallance
Journal:  J Inherit Metab Dis       Date:  2013-01-08       Impact factor: 4.982

3.  Fatty Acid oxidation disorder with secondary mitochondrial energy production defect: a case report.

Authors:  Seema Pavaman Sindgikar; Deepthi Raran Veetil; Rathika D Shenoy; Vijaya Shenoy
Journal:  Indian J Clin Biochem       Date:  2013-10-04

4.  Effects of fasting, feeding and exercise on plasma acylcarnitines among subjects with CPT2D, VLCADD and LCHADD/TFPD.

Authors:  Gabriela Elizondo; Dietrich Matern; Jerry Vockley; Cary O Harding; Melanie B Gillingham
Journal:  Mol Genet Metab       Date:  2020-09-06       Impact factor: 4.797

Review 5.  Clinical and biochemical monitoring of patients with fatty acid oxidation disorders.

Authors:  Allan Meldgaard Lund; Flemming Skovby; Helle Vestergaard; Mette Christensen; Ernst Christensen
Journal:  J Inherit Metab Dis       Date:  2010-01-12       Impact factor: 4.982

6.  Altered body composition and energy expenditure but normal glucose tolerance among humans with a long-chain fatty acid oxidation disorder.

Authors:  Melanie B Gillingham; Cary O Harding; Dale A Schoeller; Dietrich Matern; Jonathan Q Purnell
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-09-24       Impact factor: 4.310

Review 7.  Mitochondrial trifunctional protein defects: clinical implications and therapeutic approaches.

Authors:  R Scott Rector; R Mark Payne; Jamal A Ibdah
Journal:  Adv Drug Deliv Rev       Date:  2008-07-04       Impact factor: 15.470

8.  Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity.

Authors:  Chi Chen; Kristopher W Krausz; Yatrik M Shah; Jeffrey R Idle; Frank J Gonzalez
Journal:  Chem Res Toxicol       Date:  2009-04       Impact factor: 3.739

9.  Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.

Authors:  Melanie B Gillingham; William E Connor; Dietrich Matern; Piero Rinaldo; Terry Burlingame; Kaatje Meeuws; Cary O Harding
Journal:  Mol Genet Metab       Date:  2003-06       Impact factor: 4.797

10.  Laboratory analysis of acylcarnitines, 2020 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Marcus J Miller; Kristina Cusmano-Ozog; Devin Oglesbee; Sarah Young
Journal:  Genet Med       Date:  2020-10-19       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.